In this trial’s cohort, a strong correlation between the number of predicted neo-antigens that bind class I major histocompatibility complex (MHC) and tumor mutation burden was observed (Pearson’s correlation > 0.99; S4A and S3B Figs). The gene discussed is HLA-C; the disease is neoplasm.